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Background: Moniliophthora perniciosa (Stahel) Aime & Phillips-Mora is the causal agent
of witches’ broom disease (WBD) in cacao (Theobroma cacao). When the mitochondrial
genome of this fungus had been completely sequenced, an integrated linear-type
plasmid that encodes viral-like RNA polymerases was found. The structure of this
polymerase was previously constructed using a homology modeling approach.
Methods: Using a virtual screening process, accessing the Kegg, PubChem and ZINC
databases, we selected the eight most probable macrocyclic polymerase inhibitors to
test against M. perniciosa RNA polymerase (RPO). AutoDock Vina was used to perform
docking calculations for each molecule. This software returned affinity energy values
for several ligand conformations. Subsequently, we used PyMOL 1.4 and Ligand Scout
3.1 to check the stereochemistry of chiral carbons, substructure, superstructure,
number of rotatable bonds, number of rings, number of donor groups, and hydrogen
bond receptors.
Results: On the basis of this evidence we selected Rifampicin, a bacterial RNA
polymerase inhibitor, and then AMBER 12 was used to simulate the behavior of the
RPO-Rifampicin complex after a set of 5000 ps and up to 300 K in water. This
calculation returned a graph of potential energy against simulation time and showed
that the ligand remained inside the active site after the simulation was complete, with
an average energy of -15 x 102 Kcal/Mol.
Conclusions: The results indicate that Rifampicin could be a good inhibitor for testing
in vitro and in vivo against M. perniciosa.
Keywords: Moniliophthora perniciosa, RNA polymerase, Rifampicin, Docking,
MM/PBSABackground
Moniliophthora perniciosa (Stahel) Aime & Phillips-Mora is the causal agent of
witches’ broom disease (WBD) in cacao (Theobroma cacao). When the mitochondrial
genome (http://www.ncbi.nlm.nih.gov/genomes/GenomesGroup.cgi?taxid=4751&opt=
organelle/) of this fungus had been completely sequenced, an integrated linear-type
plasmid that encodes viral-like DNA and RNA polymerases was found [1].© 2013 Andrade et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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direct target of most regulators of transcription [2]. The enzyme from the M. perniciosa
mitochondrial plasmid (RPO) is a 766 amino acid DNA-dependent RNA polymerase
belonging to the single chain family of polymerases, which occur in viruses and cellular
organelles [3]. Its active site is distributed between two domains, Palm (Asp457 and
Asp695) and Fingers (Tyr537 and Lys529), involved in transcription [3-5]. The mechan-
ism of transcription by this enzyme shares several similarities with other multichain
RNA polymerases [3,6], so it could have inhibitors in common with other polymerases.
Rifampicin is a macrocyclic molecule the ansamycin family. It contains a methyl-
piperazinyliminomethyl side chain at position 3, a cyclopentyl-piperazinyliminomethyl
side chain at position 3, and a cyclic spiro-piperidyl side chain at positions 3 and 4 [7].
This drug has been used since 1968 to combat Mycobacterium tuberculosis but is con-
sidered a broad-spectrum antibiotic [8,9]. It has a high capacity to bind and inhibit
DNA-dependent RNA polymerases (RNAP) from bacteria through its specific inter-
action is with the polymerase β subunit [10]. The essential catalytic core of RNAP is
evolutionarily conserved among all cellular organisms [9].
Virtual structure-based screening has become prominent in drug discovery, using
protein targets [11,12]. Several free ligand databases are widely available today.
Searching for molecules that can complex with target proteins can be done either by
keywords (e.g. Kegg and PubChem databases) or by using a structure-activity relation-
ship, available in the Zinc [13] and PubChem databases.
One of the most important techniques for receptor-based drug design is molecular
docking [11]. Using crystallographic or modeled protein structures, molecular docking
is often employed to screen compound libraries and to predict the conformation of a
protein-ligand complex and calculate its affinity energy [12]. In general, docking pro-
grams such as AutoDock Vina [14] generate multiple protein-ligand conformations by
sampling the ligand’s probable conformations in the binding pocket of the target pro-
tein, using flexible ligand-rigid receptor docking [11,14]. Scoring functions are used for
docking calculations by these programs in an attempt to approximate the standard
chemical potentials of the system [14]. AutoDock Vina uses a force-field-based scoring
function approach to estimate binding affinities by calculating the non-bonded interac-
tions based on traditional force fields, identify the correct binding position of a ligand,
and rank ligands by their predicted binding affinities [11,14]. On the other hand, the
problems of molecular docking as a screening tool have been widely discussed: the
scoring functions are in general inaccurate and neglect solvent-related terms, and pro-
tein flexibility is ignored [12]. Coupled Molecular Docking and Molecular Dynamics is
a good way to solve this problem because it can treat both proteins and ligands in a
flexible manner, allowing the binding site to be relaxed around the ligand [11,12,15].
Molecular mechanics/Poisson-Boltzmann surface area (MM/PBSA) combines mo-
lecular mechanics energy and implicit solvation models and is more rigorous than most
empirical or knowledge-based scoring functions [11,12]. It allows for rigorous free-
energy decomposition into contributions originating from different groups of atoms or
types of interaction [11,16]. In the MM/PB-SA method the free energy is calculated
using snapshots of solute molecules obtained from explicit-solvent MD simulation [12].
The aim of this study was to search a series of molecules likely to form complexes
with the RPO from M. perniciosa, available at the Kegg, PubChem and Zinc databases,
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Dynamics - MM / PBSA - approach.
Methods
Ligand searching
We searched initially by keywords and by nucleoside molecules in the Kegg (http://
www.genome.jp/kegg/) and PubChem (http://pubchem.ncbi.nlm.nih.gov/) databases.
Only molecules described as inhibitors of RNA polymerases were selected from the
outputs. All 2D structures were copied in Similes format for comparison with other
Zinc database (http://zinc.docking.org/) molecules; this increases the number of mole-
cules that can be used for docking, starting from a known ligand. The 3D structures
of these molecules were downloaded in mol2 and pdb formats for use in Virtual
Screening, which was carried out by Molecular Docking and Molecular Dynamics.
Following a protocol described by Irwin and Schoichet (2005) [13], molecules
obtained from the Zinc database were selected for comparison, given 95-99% similar-
ity, with the structures found in the Kegg and PubChem databases. In addition, se-
lected structures were downloaded in mol2 and pdb formats for subsequent Docking
Studies and Molecular Dynamics.
Docking studies
The structures downloaded from the Kegg, Pubchem and Zinc databases were first
checked in PyMOL 1.4 [17] to evaluate the presence or absence of hydrogen, the
stereochemistry of chiral carbons, substructure, superstructure, number of rotatable
bonds, number of rings and number of hydrogen acceptors and donors.
The ligand and receptor (RPO) molecules were prepared in AutoDockTools 1.5.6 [18].
All polar hydrogens were added to the receptor and Kollman United Atomic Charges
were computed. For all ligands we added polar hydrogens and computed the Gasteiger
charges. The grid definition, adjusted to the RPO active site, was set up manually by fol-
lowing the recommendations of the program manual [14,18]. The structures of the lig-
and and receptor were then saved in pqbqt format to be used for docking calculations.
AutoDock Vina was used to perform Docking Scoring for each ligand-receptor complex
[14]. Before running each Docking calculation, a configuration file was generated with
information about grid size and coordinates and indicating the ligand and receptor files.
The reports for each calculation were analyzed to obtain affinity energy (Kcal/mol)
values for each ligand conformation in its respective complex. In addition, we used
PyMOL 1.4 to verify the number of hydrogen bonds and non-covalent interactions be-
tween each ligand conformation and the catalytic residues of RPO that are involved in
the recognition and polymerization mechanisms. In order to optimize the choice of an
ideal complex we selected just one ligand that fit best in the RPO active site, considering
all stereochemical aspects previously evaluated and the free-energy results.
Molecular dynamics of complex
In this study we used the MM/PBSA protocol to calculate affinity and stability in the
ligand-receptor RPO complex interaction, using the package Amber 12 [19]. Initially,
we used the Antechamber program to make the ff99 force field recognize the types of
atom in both ligand and receptor and avoid errors during the calculations.
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immersed in a rectangular box of TIP3P water molecules. Following the protocol we used
Sander to carry out a Molecular Dynamics (MD) equilibrium, restricted to a region of the
protein that contains the active site (amino acids 457-695), according to the following pa-
rameters: 1000 cycles of steepest descent and 1000 cycles of conjugate gradient
minimization, heating MD for 200 picoseconds (ps), density equilibrium for 200 ps,Figure 1 2D structures of the eight selected compounds used for docking studies.
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system equilibrated we followed this with the MM/PBSA protocol [11,19,20]. We then sim-
ulated a total of 4000 ps production steps of Molecular Dynamics, divided into four sets of
1000 ps (prod1, prod2, prod3 and prod4), saving the coordinates every 10 ps. Furthermore,
we used the mm_pbsa.pl script to extract snapshots (without the water) from our produc-
tion runs and obtain its trajectories. In addition, we checked the stability of the complex by
plotting Potential Energy × Time (ps) and RMSD × Time (ps) graphs from all simulation
trajectories. As a final step, we used the ambpdb command to generate a pdb file of the
complex after the last stage of the Molecular Dynamics, and this structure was analyzed in
PyMOL 1.4 to verify whether the ligand remained in the active site after the process was
complete. In addition, Ligand Scout 3.1 [21] was used to generate 2D and 3D interaction
maps of RPO-Rifampicin, presenting Hydrogen Bond Acceptors and Donors (HBA and
HBD) and all hydrophobic interactions in the active site.
Results and discussion
Structures and binding energies of RPO complexes from AutoDock Vina
After searching the KEGG, Pubchem and Zinc databases, we selected eight structures
(Figure 1) that could interact strongly with RPO and belonged to different classes. Reli-
able prediction of complex interactions is essential for choosing a potential ligand in
virtual screening methodologies, and that requires an appropriate tool capable of
assessing the energy of the binding protein, indicating the quality of interaction [22].
The results of Molecular Docking with AutoDock Vina for different ligand-RPO com-
plexes are presented in Table 1 in terms of the dominant configuration with highest af-
finity energy. The Docking scores returned by AutoDock Vina indicate that the ligand
Rifampicin has the top rank as a good RPO inhibitor. We also evaluated other charac-
teristics of all the ligands screened, such as H-bond donors and H-bond acceptors, and
the capacity of at least one conformation of each ligand to bind to amino acids in the
active site pocket of RPO when the complex is formed [3]. Among the molecules stud-
ied, Rifampicin bound best to the amino acids in the RPO active site and it presented a
high affinity energy (Table 1) in docking calculations for all docking positions. In
Figure 2 we show that Rifampicin fits inside the hydrophobic pocket of RPO. This mol-
ecule forms several hydrogen bonds (HBA and HBD) with amino acids in the RPO ac-
tive site region - one with Asp457 (HBA), two with Arg404 (HBD), two with Arg525
(HBD), one with Ser459 (HBD), and two with Tyr494 (HBD) – as well as hydrophobicTable 1 Potential RPO inhibitors selected from the Kegg, PubChem and Zinc databases
used in docking studies
Molecule Affinity (kcal/mol) H-bond donor H-bond acceptor
Rifampicin -10.4 6 15
Rifapentine -9 6 15
Rifabutin Mycobutin -8 5 14
Zinc5220312 -5.2 5 7
Zinc5124992 -5 2 8
Zinc5220316 -4.7 5 7
Zinc5220339 -5.1 5 7
Zinc22173122 -5.5 4 4
Figure 2 RPO active pocket showing Rifampicin interaction. The catalytic amino acids are in the red region.
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and 4). According to some authors, Asp457 in the active sites of the RPOs of several
organisms is involved in transcription [3-5,23]. In Escherichia coli Rifampicin binds in a
pocket of the RNAP β subunit deep within the DNA/RNA channel and blocks the
RNA exit pathway [24]. In another study, Campbell et al. (2001) [9] described a 3.3 Ǻ
crystal structure of Thermus aquaticus RNA polymerase complexed with Rifampicin, and
the results of their biochemical experiments indicated that its predominant effect is to
block the path of the elongating RNA transcript directly at the 5’ end when the transcript
reaches either two or three nucleotides in length [25].Figure 3 2D interaction map presenting molecular interactions between RPO catalytic amino acids
and Rifampicin. Green arrow shows Hydrogen Bond Acceptor (HBA) and red arrow shows Hydrogen Bond
Donor (HBD). Hydrophobic interactions are represented by yellow spheres.
Figure 4 3D interaction map presenting molecular interactions between RPO active site and Rifampicin.
Green spheres show Hydrogen Bond Acceptors (HBA) and red spheres show Hydrogen Bond Donors (HBD).
Hydrophobic interactions are represented by yellow spheres.
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stricted to prokaryotes. An RNA-dependent RNA polymerase (RdRp) is an attractive
target for anti-HCV agents [26]. However, we found no articles that dealt specifically
with the use of inhibitors of fungal polymerases or polymerases encoded by mitochon-
drial genes. On the other hand, many authors report that all cellular RNA polymerases
are relatively conserved in amino acid sequence and catalytic mechanism [2,7,9,23], We
can therefore understand why we generally find the same class (macrocyclic) of RNA
polymerase inhibitors acting on different groups of organisms. In addition, Rifampicin
can probably act in vitro and in vivo, inhibiting mitochondrial transcription by RPO and
thus blocking the mitochondrial metabolism of M. perniciosa.Figure 5 Graph of potential energy of RPO-Rifampicin complex during 5000 ps molecular
dynamics simulation.
Figure 6 RMSD graph of RPO-Rifampicin complex during 5000 ps molecular dynamics simulation.
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Using a Molecular Dynamics approach we analyzed the performance and stability of
the RPO-Rifampicin complex. We then evaluated the potential energy of the complex
during the simulation process and its final energy. The graph in Figure 5 shows that
above 600 ps simulation the complex has already reached the average potential energy
of the system, which is maintained until the end of the simulation. In addition, the po-
tential energy during the plateau shows that the structure of this complex is perfectly
plausible. The final energy reached at exactly 5000 ps was -15 × 102 Kcal/Mol. We also
considered the RMSD generated during all processes (Figure 6), and we noticed that
the value converged around 1500 ps simulation.
The pdb of the complex, generated after molecular dynamics, showed that Rifampicin
remains within the active site of RPO after 5000 ps of simulation. Furthermore, we
can infer that this simulation time was sufficient to show that Rifampicin could
block M. perniciosa RPO activity.Conclusions
In this article we describe the selection of one potential inhibitor of the M. perniciosa
mitochondrial plasmid RNA polymerase from among eight molecules found in public
databases, using a virtual screening approach. Rifampicin is a bacterial RNAPs inhibi-
tor; nevertheless it forms a very stable complex with RPO, perhaps because this type of
enzyme is highly conserved among organisms. Rifampicin forms complexes with
exactly those amino acids in the active site pocket that are involved in transcription by
RPO. This integration remained stable throughout the 5000 ps of Molecular Dynamics.
In a further step, we could analyze different mechanisms of Biomolecular Simula-
tion to describe the mechanism by which Rifampicin inhibits the RPO, and whether
Rifampicin will acquire different conformations within this process that can effectively
interact within the active site of this enzyme.
We cannot discard use of the other ligands described in Table 1 as potential inhibi-
tors of RPO or of others described as macrocyclic. Rifampicin was selected because it
forms the best ligand-complex interaction. In future work we will perform biochemical
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against M. perniciosa by making RPO-dependent transcription unfeasible.
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